

Patient-Focused Interactive Treatment Tool:

Key Information You Need to Know About Your Multiple Myeloma Diagnosis

This patient-focused treatment tool (www.clinicaloptions.com/MyelomaPatientTool) was developed in partnership by Clinical Care Options and cancerGRACE.org for patients diagnosed with multiple myeloma. The goal of this tool is to help you better understand your cancer diagnosis and treatment options so you can become a partner with your oncology care team.

To most effectively use the tool, it is recommended that you have as much information about your cancer as possible before you begin. If you do not have this information yet, you can ask your hematologist or oncologist to help you fill out this checklist with useful questions about your diagnosis.

You can then enter the specific information about your cancer into the tool by answering a series of multiple-choice questions. Once all of the information is entered, the tool will provide treatment choices from 5 myeloma experts according to the answers you choose.

What type of therapy are you and your hematologist/ oncologist considering?

- ☐ Induction therapy
- ☐ Maintenance therapy
- ☐ Relapsed/refractory therapy

If you are considering induction therapy:

1. Are you eligible for autologous stem cell transplantation?

- ☐ Yes
- ☐ No

2. What is your ECOG performance status?

- ☐ ≤ 2
- ☐ > 2

3. What is your R-ISS stage?

- ☐ Stage I
- ☐ Stage II
- ☐ Stage III

4. Do you have high-risk cytogenetics?

- ☐ Yes
- ☐ No

5. Which of the following comorbidities is most likely to influence the treatment decision for you?

- ☐ Renal insufficiency
- ☐ Peripheral neuropathy
- ☐ Cardiac dysfunction
- ☐ None of the above

If you are considering maintenance therapy:

1. Are you eligible for autologous stem cell transplantation?

- ☐ Yes
- ☐ No

2. What type of induction therapy did you receive?

- ☐ IMiD-based induction
- ☐ PI-based induction
- ☐ IMiD and PI-based induction

3. Did you receive an anti-CD38 antibody as part of induction?

- ☐ Yes
- ☐ No

4. Do you have high-risk cytogenetics?

- ☐ Yes
- ☐ No

5. Which of the following comorbidities is most likely to influence the treatment decision for you?

- ☐ Renal insufficiency
- ☐ Peripheral neuropathy
- ☐ Cardiac dysfunction
- ☐ None of the above

Please continue the questionnaire on the next page.



Global
Resource for
Advancing
Cancer
Education



CLINICAL CARE OPTIONS®
ONCOLOGY

If you are considering therapy for relapsed/refractory disease:

1. Is your disease refractory to lenalidomide (Revlimid) or bortezomib/ixazomib (Velcade/Sarclisa)?

- ☐ No, not refractory to any treatment *[skip to question 4]*
- ☐ Refractory to lenalidomide (Revlimid) only *[skip to question 4]*
- ☐ Refractory to lenalidomide (Revlimid) and bortezomib/ixazomib (Velcade/Sarclisa)
- ☐ Refractory to bortezomib/ixazomib (Velcade/Sarclisa) only

[If you answered "Refractory to lenalidomide (Revlimid)"]

2. Is your disease refractory to any other agent(s) besides lenalidomide (Revlimid)?

- ☐ No, only refractory to lenalidomide (Revlimid)
- ☐ Carfilzomib (Kyprolis)
- ☐ Pomalidomide (Pomalyst) and daratumumab (Darzalex)

[If you answered "Refractory to lenalidomide (Revlimid) and bortezomib/ixazomib (Velcade/Sarclisa)"]

3. Is your disease refractory to any other agent(s) besides lenalidomide (Revlimid) and bortezomib/ixazomib (Velcade/Sarclisa)?

- ☐ No, only refractory to lenalidomide (Revlimid) and bortezomib/ixazomib (Velcade/Sarclisa)
- ☐ Pomalidomide (Pomalyst)
- ☐ Daratumumab (Darzalex)
- ☐ Elotuzumab (Empliciti)
- ☐ Carfilzomib (Kyprolis) and daratumumab (Darzalex)
- ☐ Carfilzomib (Kyprolis) and pomalidomide (Pomalyst)
- ☐ Carfilzomib (Kyprolis), pomalidomide (Pomalyst), and daratumumab (Darzalex)

4. Do you have high-risk cytogenetics?

- ☐ Yes
- ☐ No

5. What is your ECOG performance status

- ☐ ≤ 2
- ☐ > 2

6. Which of the following comorbidities is most likely to influence the treatment decision for you

- ☐ Renal insufficiency
- ☐ Peripheral neuropathy
- ☐ Cardiac dysfunction
- ☐ None of the above

For additional tips, see the section on "[How to Talk to Your Oncologist](#)" in the online tool.

If you are a healthcare provider, you can find CCO's clinician-focused tool here: <https://www.clinicaloptions.com/MyelomaTool>.



Global
Resource for
Advancing
Cancer
Education



CLINICAL CARE OPTIONS®
ONCOLOGY